Latest gross profit for BCTX: $-70K, below the Healthcare sector average of $67B.
Get informed when a big investor buys or sells
+ FollowAs of Apr 30, 2026
Trailing 12 months ending Apr 30, 2026
BriaCell Therapeutics (BCTX) currently reports a gross profit of $-70K as of April 2026. In the prior-year period, the figure was $0. That is below the Healthcare sector average of $67B. Use the charts on this page to explore BriaCell Therapeutics's gross profit history and peer comparisons.
BriaCell Therapeutics's gross profit changed from $0 to $-70K (period ending April 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
BriaCell Therapeutics's gross profit of $-70K is lower than the Healthcare sector average of $67B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
BriaCell Therapeutics reported $-70K in gross profit as of April 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current gross profit of $-70K, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $67B. From there, open related valuation or income-statement pages for BriaCell Therapeutics, and consider following BCTX for alerts when major investors trade the stock.